These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 33356529)

  • 1. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
    Armstrong AJ; Shore ND; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A
    J Urol; 2021 May; 205(5):1361-1371. PubMed ID: 33356529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
    Evans CP; Higano CS; Keane T; Andriole G; Saad F; Iversen P; Miller K; Kim CS; Kimura G; Armstrong AJ; Sternberg CN; Loriot Y; de Bono J; Noonberg SB; Mansbach H; Bhattacharya S; Perabo F; Beer TM; Tombal B
    Eur Urol; 2016 Oct; 70(4):675-683. PubMed ID: 27006332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
    Stenzl A; Dunshee C; De Giorgi U; Alekseev B; Iguchi T; Szmulewitz RZ; Flaig TW; Tombal B; Morlock R; Ivanescu C; Ramaswamy K; Saad F; Armstrong AJ
    Eur Urol; 2020 Oct; 78(4):603-614. PubMed ID: 32336645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
    Iguchi T; Kimura G; Fukasawa S; Suzuki H; Uemura H; Nishimura K; Matsumoto H; Yokomizo A; Armstrong AJ; Rosbrook B; Sugg J; Baron B; Chen L; Kunieda F; Stenzl A
    Int J Urol; 2021 Jul; 28(7):765-773. PubMed ID: 33955599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
    Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
    J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.
    Gomez-Veiga F; Szmulewitz RZ; Holzbeierlein J; Azad AA; Iguchi T; Villers A; Alcaraz A; Alekseev B; Shore ND; Rosbrook B; Zohren F; Ma J; Haas GP; Stenzl A; Armstrong AJ
    Eur Urol Oncol; 2024 Aug; 7(4):860-869. PubMed ID: 38072761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.
    Azad AA; Armstrong AJ; Alcaraz A; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Alekseev B; Iguchi T; Shore ND; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):274-282. PubMed ID: 34420037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
    Taplin ME; Armstrong AJ; Lin P; Krivoshik A; Phung D; Parli T; Tombal B; Beer TM
    J Urol; 2017 Dec; 198(6):1324-1332. PubMed ID: 28736322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
    Armstrong AJ; Iguchi T; Azad AA; Villers A; Alekseev B; Petrylak DP; Szmulewitz RZ; Alcaraz A; Shore ND; Holzbeierlein J; Gomez-Veiga F; Rosbrook B; Zohren F; Haas GP; Gourgiotti G; El-Chaar N; Stenzl A
    Eur Urol; 2023 Aug; 84(2):229-241. PubMed ID: 37179240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
    Kapoor R; Deek MP; McIntyre R; Raman N; Kummerlowe M; Chen I; Gaver M; Wang H; Denmeade S; Lotan T; Paller C; Markowski M; Carducci M; Eisenberger M; Beer TM; Song DY; DeWeese TL; Hearn JW; Greco S; DeVille C; Desai NB; Heath EI; Liauw S; Spratt DE; Hung AY; Antonarakis ES; Tran PT
    BMC Cancer; 2019 Jun; 19(1):572. PubMed ID: 31196032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
    Armstrong AJ; Al-Adhami M; Lin P; Parli T; Sugg J; Steinberg J; Tombal B; Sternberg CN; de Bono J; Scher HI; Beer TM
    JAMA Oncol; 2020 Feb; 6(2):217-225. PubMed ID: 31830211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
    Armstrong AJ; Azad AA; Iguchi T; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Alcaraz A; Alekseev B; Shore ND; Gomez-Veiga F; Rosbrook B; Zohren F; Yamada S; Haas GP; Stenzl A
    J Clin Oncol; 2022 May; 40(15):1616-1622. PubMed ID: 35420921
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
    Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
    Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
    Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
    J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.
    Sternberg CN; de Bono JS; Chi KN; Fizazi K; Mulders P; Cerbone L; Hirmand M; Forer D; Scher HI
    Ann Oncol; 2014 Feb; 25(2):429-34. PubMed ID: 24478320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
    Graff JN; Baciarello G; Armstrong AJ; Higano CS; Iversen P; Flaig TW; Forer D; Parli T; Phung D; Tombal B; Beer TM; Sternberg CN
    Ann Oncol; 2016 Feb; 27(2):286-94. PubMed ID: 26578735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
    Stenzl A; Szmulewitz RZ; Petrylak D; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Gomez-Veiga F; Ivanescu C; Rosbrook B; Ramaswamy K; Ganguli A; Haas GP; Armstrong AJ
    Prostate; 2022 Sep; 82(13):1237-1247. PubMed ID: 35675470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
    Sweeney CJ; Martin AJ; Stockler MR; Begbie S; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx GM; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Reaume MN; Sandhu SK; Tan A; Tan TH; Thomson A; Tu E; Vera-Badillo F; Williams SG; Yip S; Zhang AY; Zielinski RR; Davis ID;
    Eur Urol; 2021 Sep; 80(3):275-279. PubMed ID: 34030924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
    Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
    Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
    J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.